Contera Pharma, subsidiary of Bukwang, raises 51 billion KRW in Series B financing round

Contera Pharma (“Contera”), subsidiary of Bukwang Pharmaceutical (“Bukwang”), announced 51 billion KRW Series B financing from Korean institutional investors. The size of the current round has increased more than 17-fold compared to series A financing in 2019. Contera, is focused on developing innovative drugs for the treatment of debilitating central nervous system (CNS) disorders. The […]

Contera Pharma opens office in Seoul, Korea

To strengthen its activities Contera Pharma has today opened an office in Seoul, Korea. The Seoul office will be headed by Minchang Kwon, Managing Director and Jai Hong Kwon, CFO. John Bondo Hansen, CEO says: Our new Seoul office will be a valuable addition to the Contera organization. I warmly welcome Minchang Kwon and Jai […]

Bukwang receives US FDA approval for JM-010 phase 2 clinical study IND

Contera Pharma is preparing for public offering in KOSDAQ Bukwang has recently received the investigational new drug (IND) clearance from the US Food and Drug Administration (FDA) to proceed with phase 2 clinical study of JM-010. JM-010, originating from a Danish bioventure company Contera Pharma, is currently under development for treating dyskinesia which emerges in […]

Contera Pharma, a subsidiary of Bukwang Pharmaceutical, attracts investment from Medici Investment

3 million dollars invested by Medici Investment European Clinical phase 2 study of JM-010 to treat dyskinesia in Parkinson’s disease has been started Contera Pharma ApS (“Contera”), a subsidiary of Bukwang Pharmaceutical, has booked 3 billion KRW series A financing from Medici Investment. The proceeds from the financing will go to speed up the European […]

Bukwang Announced commencement of Phase 2 Clinical Study of JM-010 in major European countries

to be completed within 2 years Bukwang Pharmaceutical (“Bukwang”) announced today that the phase 2 clinical study of JM-010, a new potential treatment for dyskinesia in Parkinson’s disease, has recently been initiated. JM-010 is currently developed by Copenhagen-based Contera Pharma, a subsidiary of Bukwang. About 90% of patients who have been taking L-dopa for 10 […]